FORMULATION AND EVALUATION OF SUBLINGUAL TABLETS OF BUMETANIDE

Abstract

Bumetanide is a loop diuretic drug used to treat edema brought on by kidney, liver, or congestive heart failure. A formulation and evaluation attempt was undertaken for the 0.5 mg, 1 mg, and 2 mg Bumetanide Sublingual tablets. When taken orally, a fast-dissolving sublingual tablet dissolves or disperses quickly and is ingested as a liquid. To create the product, a direct blending and compression procedure using a dose-proportional, scale-up, and scale-down approach was used. Among the excipients are 0.5 percent Sucralose, 2 percent Sodium Stearyl Fumerate, 5 percent Sodium Starch Glycolate, 45.9 percent Mannitol SD 200, and 45.9 percent Pearlitol Flash (a co-processed excipient of 80 percent D-Mannitol and 20 percent Maize Starch) and 0.2 percent Capsil Orange Flavour. According to the SUPAC IR and IIG guidance documents, the composition and procedure were optimized. The finished product was judged to have a smooth mouthfeel, a pleasing flavor, and an organoleptic appearance. A member of BCS Class Ⅱ (Low Solubility and High Permeability) is bumetanide. Injection and oral tablets that are currently on the market may be replaced by the designed product.